BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 151 filers reported holding BLUEBIRD BIO INC in Q2 2024. The put-call ratio across all filers is 1.20 and the average weighting 0.0%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $54 | -23.9% | 54,714 | 0.0% | 0.00% | – |
Q1 2024 | $71 | +97.2% | 54,714 | +113.7% | 0.00% | – |
Q4 2023 | $36 | -49.3% | 25,601 | +10.4% | 0.00% | – |
Q3 2023 | $71 | -50.3% | 23,195 | -46.4% | 0.00% | – |
Q2 2023 | $143 | +31.2% | 43,313 | +27.1% | 0.00% | – |
Q1 2023 | $109 | -46.0% | 34,089 | +16.9% | 0.00% | – |
Q4 2022 | $202 | -99.9% | 29,149 | +3.3% | 0.00% | – |
Q3 2022 | $179,000 | +103.4% | 28,219 | +33.2% | 0.00% | – |
Q2 2022 | $88,000 | -12.0% | 21,191 | +2.5% | 0.00% | – |
Q1 2022 | $100,000 | -47.9% | 20,684 | +7.8% | 0.00% | – |
Q4 2021 | $192,000 | -64.4% | 19,180 | -32.1% | 0.00% | – |
Q3 2021 | $540,000 | -40.1% | 28,254 | +0.2% | 0.00% | – |
Q2 2021 | $902,000 | -96.9% | 28,195 | -97.0% | 0.00% | -100.0% |
Q1 2021 | $28,698,000 | -35.8% | 951,840 | -7.9% | 0.00% | -40.0% |
Q4 2020 | $44,733,000 | -13.9% | 1,033,820 | +7.3% | 0.01% | -16.7% |
Q3 2020 | $51,976,000 | -40.9% | 963,412 | -33.1% | 0.01% | -45.5% |
Q2 2020 | $87,937,000 | +46.3% | 1,440,641 | +10.2% | 0.01% | +10.0% |
Q1 2020 | $60,092,000 | -58.8% | 1,307,476 | -21.3% | 0.01% | -47.4% |
Q4 2019 | $145,741,000 | +20.5% | 1,660,862 | +26.1% | 0.02% | +11.8% |
Q3 2019 | $120,930,000 | -33.1% | 1,317,037 | -7.3% | 0.02% | -32.0% |
Q2 2019 | $180,721,000 | -25.2% | 1,420,760 | -7.5% | 0.02% | -30.6% |
Q1 2019 | $241,535,000 | +91.5% | 1,535,210 | +20.7% | 0.04% | +71.4% |
Q4 2018 | $126,137,000 | -67.5% | 1,271,545 | -52.1% | 0.02% | -63.2% |
Q3 2018 | $387,917,000 | -12.5% | 2,656,969 | -6.0% | 0.06% | -16.2% |
Q2 2018 | $443,398,000 | -8.8% | 2,825,093 | -0.8% | 0.07% | -11.7% |
Q1 2018 | $486,163,000 | -4.5% | 2,847,222 | -0.4% | 0.08% | -7.2% |
Q4 2017 | $508,965,000 | +35.4% | 2,857,747 | +4.4% | 0.08% | +29.7% |
Q3 2017 | $375,876,000 | +22.6% | 2,736,626 | -6.2% | 0.06% | +16.4% |
Q2 2017 | $306,585,000 | +9.6% | 2,918,472 | -5.1% | 0.06% | +5.8% |
Q1 2017 | $279,685,000 | +37.9% | 3,076,847 | -6.4% | 0.05% | +30.0% |
Q4 2016 | $202,880,000 | -11.1% | 3,288,161 | -2.3% | 0.04% | -13.0% |
Q3 2016 | $228,134,000 | +115.6% | 3,365,797 | +37.7% | 0.05% | +109.1% |
Q2 2016 | $105,817,000 | +15.2% | 2,444,381 | +13.1% | 0.02% | +10.0% |
Q1 2016 | $91,828,000 | -28.7% | 2,160,663 | +7.7% | 0.02% | -25.9% |
Q4 2015 | $128,781,000 | -17.8% | 2,005,303 | +9.6% | 0.03% | -22.9% |
Q3 2015 | $156,589,000 | -48.1% | 1,830,380 | +2.2% | 0.04% | -43.5% |
Q2 2015 | $301,591,000 | +30.0% | 1,791,241 | -6.8% | 0.06% | +29.2% |
Q1 2015 | $232,032,000 | +66.8% | 1,921,268 | +26.7% | 0.05% | +60.0% |
Q4 2014 | $139,134,000 | +263.3% | 1,516,944 | +42.1% | 0.03% | +275.0% |
Q3 2014 | $38,294,000 | +843.0% | 1,067,271 | +497.6% | 0.01% | +700.0% |
Q1 2014 | $4,061,000 | -80.0% | 178,585 | -81.5% | 0.00% | -50.0% |
Q4 2013 | $20,292,000 | – | 967,234 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 1,964,000 | $59,215,000 | 1.36% |
Birchview Capital, LP | 75,500 | $2,276,000 | 1.35% |
Camber Capital Management LP | 1,000,000 | $30,150,000 | 1.04% |
Sessa Capital IM, L.P. | 875,000 | $26,381,000 | 1.02% |
Bain Capital Life Sciences Investors, LLC | 538,179 | $16,226,000 | 0.92% |
Tarsadia Capital, LLC | 100,000 | $3,015,000 | 0.81% |
Bullseye Asset Management LLC | 67,872 | $2,046,000 | 0.76% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,304,246 | $39,323,000 | 0.58% |
MANGROVE PARTNERS IM, LLC | 175,178 | $5,282,000 | 0.53% |
Parametrica Management Ltd | 37,712 | $1,080,000 | 0.52% |